XOMA Royalty Sets Merger Closing Date, Redeems Preferred Stock, and Announces CVR Record Date

summarizeSummary

XOMA Royalty Corp announced the expected closing date for its acquisition by Ligand Pharmaceuticals, initiated the redemption of all preferred stock, and set the record date for contingent value rights (CVRs) distribution.

check_boxKey Events

• Merger Closing Date Set

  The acquisition of XOMA Royalty by Ligand Pharmaceuticals is expected to close on or about July 14, 2026.

• Preferred Stock Redemption Initiated

  All outstanding Series A and Series B preferred stock, totaling approximately $68.6 million, will be redeemed on July 14, 2026, at $25.00 per share/depositary share plus accrued dividends. This represents about 9.3% of the company's market capitalization.

• CVR Record Date Announced

  A record date of July 13, 2026, has been set for common stockholders to receive contingent value rights (CVRs) as additional merger consideration, related to the Janssen Litigation.

auto_awesomeAnalysis

This filing provides critical updates on the pending acquisition of XOMA Royalty by Ligand Pharmaceuticals. The company has set an expected closing date for the merger, initiated the redemption of all outstanding preferred stock totaling approximately $68.6 million, and established the record date for the distribution of contingent value rights (CVRs) to common shareholders. These actions are essential steps towards finalizing the acquisition and clarifying the full consideration for investors.